Finance

Beta
Lists
HEMO:LON
Hemogenyx Pharmaceuticals PLC
GBX 738.50
+2.00%
(+14.50) 1D
Jun 5, 1:15:07 PM GMT+1  ·   GBX
All symbols
SymbolPriceChange% Change
Generating top insights for HEMO...
Open
GBX 743.00
High
GBX 750.00
Low
GBX 719.00
Mkt. cap
50.22M
Avg. vol.
25.82K
Volume
16.24K
52-wk high
GBX 1,800.00
52-wk low
GBX 124.00
EPS
-GBX 2.20
Shares outstanding
6.80M
No. of employees
16
Open
GBX 743.00
High
GBX 750.00
Low
GBX 719.00
Mkt. cap
50.22M
Avg. vol.
25.82K
Volume
16.24K
52-wk high
GBX 1,800.00
52-wk low
GBX 124.00
EPS
-GBX 2.20
Shares outstanding
6.80M
No. of employees
16
News stories
From sources across the web
About Hemogenyx Pharmaceuticals PLC
CEO-
Employees16
Founded2013
Headquarters-
SectorBiotechnology
Websitehemogenyx.com
Previous reportsAll values in GBP
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in GBP
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.13M
1.13M
2.06M
2.06M
Operating expense
1.32M
1.32M
2.16M
2.16M
Total operating expenses
1.32M
1.32M
2.16M
2.16M
Operating income
-1.32M
-1.32M
-2.16M
-2.16M
Other non operating income
-
-
-1.15M
-1.15M
EBT including unusual items
-2.50M
-2.50M
-2.38M
-2.38M
EBT excluding unusual items
-2.50M
-2.50M
-2.24M
-2.24M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
33.28K
33.28K
-33.28K
-33.28K
Net income
-2.50M
-2.50M
-2.38M
-2.38M
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
3.00
3.00
563.00
563.00
Interest expense
-59.94K
-59.94K
-54.83K
-54.83K
Net interest expenses
-59.94K
-59.94K
-54.27K
-54.27K
Depreciation and amortization charges
156.89K
156.89K
137.48K
137.48K
EBITDA
-1.27M
-1.27M
-2.13M
-2.13M
Gain or loss from assets sale
-
-
2.30K
2.30K
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer